Literature DB >> 24726923

Tryptase-PAR2 axis in experimental autoimmune prostatitis, a model for chronic pelvic pain syndrome.

Kenny Roman1, Joseph D Done, Anthony J Schaeffer, Stephen F Murphy, Praveen Thumbikat.   

Abstract

Chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) affects up to 15% of the male population and is characterized by pelvic pain. Mast cells are implicated in the murine experimental autoimmune prostatitis (EAP) model as key to chronic pelvic pain development. The mast cell mediator tryptase-β and its cognate receptor protease-activated receptor 2 (PAR2) are involved in mediating pain in other visceral disease models. Prostatic secretions and urines from CP/CPPS patients were examined for the presence of mast cell degranulation products. Tryptase-β and PAR2 expression were examined in murine EAP. Pelvic pain and inflammation were assessed in the presence or absence of PAR2 expression and upon PAR2 neutralization. Tryptase-β and carboxypeptidase A3 were elevated in CP/CPPS compared to healthy volunteers. Tryptase-β was capable of inducing pelvic pain and was increased in EAP along with its receptor PAR2. PAR2 was required for the development of chronic pelvic pain in EAP. PAR2 signaling in dorsal root ganglia led to extracellular signal-regulated kinase (ERK)1/2 phosphorylation and calcium influx. PAR2 neutralization using antibodies attenuated chronic pelvic pain in EAP. The tryptase-PAR2 axis is an important mediator of pelvic pain in EAP and may play a role in the pathogenesis of CP/CPPS.
Copyright © 2014 International Association for the Study of Pain. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  CPPS; Mast cells; Pelvic pain; Prostatitis

Mesh:

Substances:

Year:  2014        PMID: 24726923      PMCID: PMC4089501          DOI: 10.1016/j.pain.2014.04.009

Source DB:  PubMed          Journal:  Pain        ISSN: 0304-3959            Impact factor:   6.961


  22 in total

1.  The cellular basis of protease-activated receptor 2-evoked mechanical and affective pain.

Authors:  Shayne N Hassler; Moeno Kume; Juliet M Mwirigi; Ayesha Ahmad; Stephanie Shiers; Andi Wangzhou; Pradipta R Ray; Serge N Belugin; Dhananjay K Naik; Michael D Burton; Josef Vagner; Scott Boitano; Armen N Akopian; Gregory Dussor; Theodore J Price
Journal:  JCI Insight       Date:  2020-06-04

2.  A Novel, Nonpeptidic, Orally Active Bivalent Inhibitor of Human β-Tryptase.

Authors:  Sarah F Giardina; Douglas S Werner; Maneesh Pingle; Donald E Bergstrom; Lee D Arnold; Francis Barany
Journal:  Pharmacology       Date:  2018-08-22       Impact factor: 2.547

3.  TRPV1 in experimental autoimmune prostatitis.

Authors:  Kenny Roman; Christel Hall; Anthony J Schaeffer; Praveen Thumbikat
Journal:  Prostate       Date:  2019-10-01       Impact factor: 4.104

4.  Role of PAR2 in the Development of Lower Urinary Tract Dysfunction.

Authors:  Kenny Roman; Stephen F Murphy; Joseph D Done; Kevin E McKenna; Anthony J Schaeffer; Praveen Thumbikat
Journal:  J Urol       Date:  2016-02-06       Impact factor: 7.450

5.  Pediatric Eosinophilic Esophagitis Symptom Scores (PEESS v2.0) identify histologic and molecular correlates of the key clinical features of disease.

Authors:  Lisa J Martin; James P Franciosi; Margaret H Collins; J Pablo Abonia; James J Lee; Kevin A Hommel; James W Varni; J Tommie Grotjan; Michael Eby; Hua He; Keith Marsolo; Philip E Putnam; Jose M Garza; Ajay Kaul; Ting Wen; Marc E Rothenberg
Journal:  J Allergy Clin Immunol       Date:  2015-06       Impact factor: 10.793

6.  Mast cell function in prostate inflammation, fibrosis, and smooth muscle cell dysfunction.

Authors:  Goutham Pattabiraman; Ashlee J Bell-Cohn; Stephen F Murphy; Daniel J Mazur; Anthony J Schaeffer; Praveen Thumbikat
Journal:  Am J Physiol Renal Physiol       Date:  2021-08-23

Review 7.  Experimental autoimmune prostatitis: different antigens induction and antigen-specific therapy.

Authors:  Yuqian Liu; Junaid Wazir; Meng Tang; Rahat Ullah; Yueting Chen; Tingting Chen; Xiaohui Zhou
Journal:  Int Urol Nephrol       Date:  2020-11-16       Impact factor: 2.370

8.  Assessment of Perigenital Sensitivity and Prostatic Mast Cell Activation in a Mouse Model of Neonatal Maternal Separation.

Authors:  Isabella M Fuentes; Angela N Pierce; Pierce T O'Neil; Julie A Christianson
Journal:  J Vis Exp       Date:  2015-08-13       Impact factor: 1.355

9.  Protease-activated receptor 2 activation is sufficient to induce the transition to a chronic pain state.

Authors:  Dipti V Tillu; Shayne N Hassler; Carolina C Burgos-Vega; Tammie L Quinn; Robert E Sorge; Gregory Dussor; Scott Boitano; Josef Vagner; Theodore J Price
Journal:  Pain       Date:  2015-05       Impact factor: 7.926

10.  Involvement of Mast Cells in the Pathophysiology of Pain.

Authors:  Lijia Mai; Qing Liu; Fang Huang; Hongwen He; Wenguo Fan
Journal:  Front Cell Neurosci       Date:  2021-06-10       Impact factor: 5.505

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.